



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 37/02, 37/24, 37/36	A1	(11) International Publication Number: WO 93/25219 (43) International Publication Date: 23 December 1993 (23.12.93)
(21) International Application Number: PCT/US93/05203 (22) International Filing Date: 1 June 1993 (01.06.93) (30) Priority data: 07/899,070 12 June 1992 (12.06.92) US 08/051,191 16 April 1993 (16.04.93) US (71) Applicants: CEPHALON, INC. [US/US]; 145 Brandywine Parkway, West Chester, PA 19380 (US). ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY [US/US]; 1300 Morris Park Avenue, Bronx, NY 10461 (US). (72) Inventors: LEWIS, Michael, E. ; 23 Bills Way, Landenberg, PA 19350 (US). APFEL, Stuart, C. ; 218 Walker Place, West Hempstead, NY 11552 (US). KESSLER, John, A. ; Wing Road, New Canaan, CT 06840 (US).		(74) Agent: CLARK, Paul, T.; Fish & Richardson, 225 Franklin Street, Boston, MA 02110 (US). (81) Designated States: AU, BR, CA, FI, HU, JP, KR, NO, NZ, PT, RU, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: PREVENTION AND TREATMENT OF PERIPHERAL NEUROPATHY (57) Abstract The invention features a method of using insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to prevent or treat peripheral neuropathy in a mammal.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

PREVENTION AND TREATMENT OF PERIPHERAL NEUROPATHY

Background of the Invention

This invention relates to using an insulin-like growth factor-I to prevent or treat peripheral neuropathy.

5 Insulin like growth factor-I (IGF-I; somatomedin C) is a member of a family of structurally and functionally related polypeptides which also includes insulin, and insulin like growth factors II (IGF-II) and III (IGF-III). All of these protein factors may play a
10 role in neuronal development and maintenance (Recio-Pinto, E., et al., 1988, Neurochem. Int. 12:397-414). In addition, there is evidence that the levels of IGF-I and IGF-II increase substantially during regeneration after sciatic nerve transection (Hansson, H.A., et al., 1986,
15 Acta Physiol. Scand., 126:609-614). They have been shown to promote the survival of cultured sensory and sympathetic neurons (Ishii, D.N., et al., 1987, In: Insulin, IGFs and Their Receptors in the Central Nervous System, eds., Raizada, M.K., et al., Plenum Press, NY,
20 pp. 315-348) and, in the case of IGF-I, to promote the survival of cortical neurons (Aizenman, Y., et al., 1987, Brain Res., 406:32-42). Finally, studies both in-vitro and in-vivo have demonstrated that IGF-I and IGF-II promote motor neuron survival and neurite outgrowth
25 (Caroni, P., et al., 1990, J. Cell Biol., 110:1307-1317).

Peripheral neuropathy generally refers to a disorder that affects the peripheral nerves, most often manifested as one or a combination of motor, sensory, sensorimotor, or autonomic neural dysfunction. The wide
30 variety of morphologies exhibited by peripheral neuropathies can each be uniquely attributed to an equally wide variety of causes. For instance, peripheral neuropathies can be genetically acquired, can result from

- 2 -

a systemic disease, or can be induced by a toxic agent. Some toxic agents that cause neurotoxicities are therapeutic drugs, antineoplastic agents, contaminants in foods or medicinals, and environmental and industrial pollutants.

In particular, chemotherapeutic agents known to cause sensory and/or motor neuropathies include vincristine, an antineoplastic drug used to treat haematological malignancies and sarcomas. The neurotoxicity is dose-related, and exhibits as reduced intestinal motility and peripheral neuropathy, especially in the distal muscles of the hands and feet, postural hypotension, and atony of the urinary bladder. Similar problems have been documented with taxol and cisplatin (Mollman, J.E., 1990, New Eng Jour Med. 322:126-127), although cisplatin-related neurotoxicity can be alleviated with nerve growth factor (NGF) (Apfel, S.C. et al., 1992, Annals of Neurology 31:76-80). Although the neurotoxicity is sometimes reversible after removal of the neurotoxic agent, recovery can be a very slow process (Legha, S., 1986, Medical Toxicology 1:421-427; Olesen, et al., 1991, Drug Safety 6:302-314).

There are a number of inherited peripheral neuropathies, including: Refsum's disease, Abetalipoproteinemia, Tangier disease, Krabbe's disease, Metachromatic leukodystrophy, Fabry's disease, Dejerine-Sottas syndrome, and others. Of all the inherited neuropathies, the most common by far is Charcot-Marie-Tooth Disease.

Charcot-Marie-Tooth (CMT) Disease (also known as Peroneal Muscular Atrophy, or Hereditary Motor Sensory Neuropathy (HMSN)) is the most common hereditary neurological disorder. It is characterized by weakness and atrophy, primarily of the peroneal muscles, due to segmental demyelination of peripheral nerves and

- 3 -

associated degeneration of axons and anterior horn cells. Autosomal dominant inheritance is usual, and associated degenerative CNS disorders, such as Friedreich's ataxia, are common.

5 There are two primary forms of CMT Disease. Type I (70% of cases) was believed to have demyelination as its initial pathophysiology, but distal clinical involvement suggests a primary axonal degeneration, as in Type II. Type II (30% of cases) is primarily an axonal
10 degeneration without demyelination, and may not be as severe as Type I. Nerve conduction impairment is often present at birth, though this is not a predictor of the possible age of onset or severity of progression. There are also very rare, Type III and Type IV forms, which are
15 recessively-linked.

Summary of the Invention

The invention features a method of reducing a peripheral neuropathy that is not caused by an abnormal insulin level in a mammal. The method involves
20 administering a neuropathy-reducing amount of insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to the mammal.

In various preferred embodiments, the mammal is a human, or an agricultural or domestic mammal that
25 develops a neuropathy, e.g., as a result of treatment of a neoplasm with a chemotherapeutic agent. IGF-I or IGF-III can be administered in a manner deemed effective by one skilled in the art; preferred modes of administration are intravenous administration and subcutaneous
30 injection.

As used herein, "peripheral neuropathy" refers to a disorder affecting a segment of the peripheral nervous system. The invention involves using IGF-I or IGF-III, members of the insulin family of growth factors, to
35 reduce a neurotoxicity that is not obviously or directly

- 4 -

caused by an abnormal level of insulin, including, but not limited to, distal sensorimotor neuropathy, or autonomic neuropathies such as reduced motility of the gastrointestinal tract or atony of the urinary bladder.

5 Preferred neuropathies that can be effectively treated with IGF-I or IGF-III include neuropathies associated with systemic disease, e.g., post-polio syndrome; genetically acquired neuropathies, e.g., Charcot-Marie-Tooth disease; and neuropathies caused by a toxic agent,

10 e.g., a chemotherapeutic agent, preferably vincristine.

Where IGF-I or IGF-III is used to treat a neuropathy induced by a toxic agent, it can be administered before, simultaneously with, or after exposure to the toxic agent, or before, during or after

15 administration of a chemotherapeutic. Preferably, the IGF-I and the chemotherapeutic agent are each administered at effective time intervals, during an overlapping period of treatment. The IGF-I or IGF-III can be administered to the mammal following exposure to

20 the neurotoxic agent, or following chemotherapy, to restore at least a portion of the neurofunction destroyed by the neurotoxic agent or chemotherapeutic. The chemotherapeutic can be any chemotherapeutic agent that causes neurotoxicity, preferably vincristine, taxol,

25 dideoxyinosine, or cisplatin. In a preferred example, the weight to weight ratio of IGF-I or IGF-III (des-(1-3)IGF-I), to vincristine is between 1:400 and 75:1, preferably between 1:40 and 8:1.

Where IGF-I and a chemotherapeutic agent are

30 administered simultaneously, the invention features a composition that includes a substantially pure IGF-I and a chemotherapeutic agent, in a weight to weight ratio of between 1:400 and 75:1. The chemotherapeutic agent is preferably vincristine, cisplatin, dideoxyinosine, or

35 taxol. The term "substantially pure", as used herein,

- 5 -

refers to IGF-I or IGF-III which, prior to mixing with another component of the composition, is at least 50% (by weight) of the protein present in the preparation. In preferred embodiments, at least 75%, more preferably at least 90%, and most preferably at least 99% (by weight) of the protein present in the preparation is IGF-I or IGF-III. Most preferably, the IGF-I or IGF-III used in the composition of the invention is pure as judged by amino-terminal amino acid sequence analysis.

10 By "toxic agent", or neurotoxic agent, is meant a substance that through its chemical action injures, impairs, or inhibits the activity of a component of the nervous system. The list of neurotoxic agents that cause neuropathies is lengthy, and includes, but is not limited
15 to, neoplastic agents such as vincristine, vinblastine, cisplatin, taxol, or dideoxy- compounds, e.g., dideoxyinosine; alcohol; metals; industrial toxins involved in occupational or environmental exposure; contaminants of food or medicinals; or over-doses of
20 vitamins or therapeutic drugs, e.g., antibiotics such as penicillan or chloramphenicol, or megadoses of vitamins A, D, or B6. An extensive, although not complete, list of chemical compounds with neurotoxic side-effects is found in Table 5. Although this list provides examples
25 of neurotoxic compounds, it is intended to exemplify, not limit, the scope of the invention. Other toxic agents can cause neuropathies, and can be characterized by methods known to one skilled in the art. By "exposure to a toxic agent" is meant that the toxic agent is made
30 available to, or comes into contact with, a mammal of the invention. Exposure to a toxic agent can occur by direct administration, e.g., by ingestion or administration of a food, medicinal, or therapeutic agent, e.g., a chemotherapeutic agent, by accidental contamination, or

- 6 -

by environmental exposure, e.g., aerial or aqueous exposure.

The terms IGF-I and IGF-III include fragments or analogs thereof that exhibit the biological activity of the invention, i.e., the ability to reduce a neuropathy induced by a toxic agent. Methods of determining whether an IGF-I or IGF-III fragment or analog possesses the biological activity of the invention are described below. Generally, suitable analogs and fragments will share at least 65% homology with naturally occurring IGF-I or IGF-III. The fragment polypeptides of IGF-I or IGF-III are subsets of the IGF-I, or IGF-III molecules (respectively), containing fewer amino acid residues than the native molecules. As used herein, a fragment of IGF-I or IGF-III can ordinarily be at least about 5 contiguous amino acids, and can be at least about 30-40 amino acids in length, and preferably about 50-65 amino acids in length. Preferred sequences are of 6-25 residues. A portion of the amino acids of the fragment may be substituted with conservative replacements or deletions which improve the chemical or biological stability of the product peptides. Preferably, no more than 35%, and more preferably no more than 20%, of the amino acid residues are replaced or deleted. The following examples of preferred IGF-I sequences fall within the scope of the invention: 1) IGF-I (55-70) (SEQ ID NO:1), described in a co-assigned patent application by Lewis et al. USSN 07/869,913); and 2) Long R³ IGF-I, which is a fusion protein that consists of human IGF-I with a 13 amino acid extension peptide at the N-terminus and the substitution of Arg for Glu at position 3 (Francis, G.L, et al. 1992. Art to Sci. in Tissue Culture. HyClone Laboratories, Inc. 11:3-7; GROPEP PTY.LTD. PCT Appl. WO89/05822; US Patent No. 5,164,370; PCT /AU90/00210). The peptide fragments listed herein

- 7 -

are examples only, and do not limit the scope of IGF-I peptide fragments useful in the invention.

"Homology", as used herein, refers to the sequence similarity between two polypeptide molecules. When a position in both of the two compared sequences is occupied by the same amino acid monomeric subunit, e.g., if a position in each of two polypeptide molecules is occupied by lysine, then the molecules are homologous at that position. The homology between two sequences is a function of the number of matching or homologous positions shared by the two sequences. For example, if 6 of 10 of the positions in two sequences are matched or homologous, then the two sequences are 60% homologous. By way of example, the amino acid sequences LTVSFR and LPVSAT share 50% homology.

An analog of IGF-I or IGF-III can differ from a naturally occurring IGF-I or IGF-III by conservative amino acid sequence differences or by modifications that do not affect sequence, or by both. Modifications include chemical derivatization of polypeptides, e.g., acetylation, carboxylation, glycosylation, or phosphorylation; substitution or deletion of amino acid residues that alter the binding protein affinity but do not substantially alter the receptor affinity and/or alter the biological activity of the polypeptide; or chemical alterations to the polypeptide that increase polypeptide stability.

Despite the widely disparate morphologies and causes attributed to peripheral neuropathies *in vivo*, applicants have hypothesized that IGF-I can be an effective means of preventing or treating such neuropathies in a mammal, despite the fact that these neuropathies can not be directly or obviously linked to a deficiency in, or otherwise abnormal level of, insulin. To illustrate this, applicants have shown that

- 8 -

administering IGF-I to animals given a drug with neurotoxic side effects, i.e., the anti-tumor drug vincristine, reduces the associated neurotoxicity. This finding not only alleviates the neurotoxic side-effect, but could also substantially increase the use of vincristine as an anti-tumor agent. The use of vincristine, an otherwise effective chemotherapeutic, has heretofore been limited by accompanying neurotoxicity. This finding could also similarly increase the use of other compounds limited by neurotoxicity problems. Co-administration of IGF-I or IGF-III can decrease the occurrence of these accompanying peripheral neuropathies.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments and from the claims.

Detailed Description

The drawings will first be described.

Drawings

Fig. 1 is a bar graph showing the effect of rhIGF-I on motor function after vincristine treatment.

Fig. 2 is a bar graph showing the effect of rhIGF-I on tibial nerve function after vincristine treatment.

Fig. 3 is a bar graph showing the effect of rhIGF-I on caudal nerve function after vincristine treatment.

Fig. 4 is a bar graph showing the effect of taxol and rhIGF-1 on tail-flick latencies.

Fig. 5 is a bar graph showing the effect of taxol and rhIGF-I on hot plate latencies.

Description of the Invention

It occurred to applicants that IGF-I, as well as IGF-I related proteins and peptides, might promote the functioning and/or survival of neurons otherwise at risk of losing function and/or dying due to exposure to toxic agents. To specifically test this idea, applicants have investigated whether IGF-I administration is capable of

- 9 -

preventing the neurotoxicity resulting from administration of the anti-tumor agent vincristine in an animal model. Clinically, the usefulness of vincristine is limited by the occurrence of polyneuropathy with prominent motor dysfunction, as well as sensory and autonomic abnormalities (Legha, S.S., supra). To date, there is no effective means of preventing this neuropathy short of limiting the dose of vincristine. Applicants have demonstrated that IGF-I administration is capable of preventing this debilitating and dose-limiting side effect of vincristine.

In a second test of this idea, applicants have investigated whether IGF-I administration is capable of preventing the neurotoxicity resulting from administration of the antitumor agent taxol in an animal model.

Experimental Example: Vincristine

Methods

Drug Administrations

Vincristine sulfate (Sigma Chemical, St. Louis, MO) was administered at a dose of 2 mg/kg intraperitoneally twice a week for six consecutive weeks. It was formulated at a concentration of 0.16 mg/ml normal saline.

Recombinant IGF-I (rhIGF-I) for experimental use was provided by Cephalon Inc. (West Chester, PA), and it is also commercially available from RD Systems, Inc. (Minneapolis, MN), U.B.I. (Lake Placid, NY), and Kabi Pharmacia AS (Stockholm, Sweden). The rhIGF-I was formulated for the high dose group at a concentration of 1 mg/ml, and for the low dose group at a concentration of 0.3mg/ml, in an acetic acid buffer solution with a pH of 6.0. The high dose groups (Groups 4 and 6) received 1.0mg/kg IGF-I three times a week subcutaneously for six consecutive weeks. The low dose treated groups (Groups 3

- 10 -

and 5) received 0.3mg/kg IGF-I three times a week subcutaneously for the same period of time. Groups not receiving IGF-I received subcutaneous injections of the acetic acid buffer vehicle in the same volume per weight, and according to the same schedule, as the animals receiving IGF-I.

Animals

CD1 male mice weighing between 15-20 gms at the outset were selected for this study. They were randomly distributed, 12 animals to each of the following treatment groups:

- Group #1: Control, vehicle injections only.
- Group #2: Vincristine plus IGF-I vehicle.
- Group #3: Vincristine plus low dose IGF-I.
- Group #4: Vincristine plus high dose IGF-I.
- Group #5: Low dose IGF-I alone.
- Group #6: High dose IGF-I alone.

Behavioral Testing

Incline test: After 6 weeks of treatment, the mice were tested in a blinded fashion. For this test each mouse was placed individually on a styrofoam board, which was then raised to a vertical position. The animals were timed for how long they could maintain their grip on the board without falling. The test was arbitrarily stopped after 30 seconds. The best time out of three trials was recorded.

Electrophysiological Testing

After behavioral testing, the mice underwent electrophysiological testing. Each mouse was anesthetized with halothane before recording. Compound amplitudes and distal latencies were measured in the caudal nerve of the tail. The tails were restrained and platinum-iridium needle surface electrodes were placed along the distal section of the caudal nerve. The active recording electrode was positioned at a fixed distance of

- 11 -

40mm distal to the stimulating cathode. Brief pulses of constant voltage stimulation were delivered through an anode-cathode pair positioned overlying a proximal section of the caudal nerve. Motor recordings were conducted orthodromically from the tibial nerve with electrode placement over the distal insertion of the gastrocnemius muscle. Sensory recordings were conducted orthodromically from the sural nerve with a distance of 10mm between electrodes. For each recording five to ten stimuli were averaged, and the procedure was repeated. Latency was determined from the onset of the initial depolarization and was measured to the nearest 0.1 msec. Amplitude was measured from the baseline to peak and was measured to the nearest 0.1 μ V. Rectal temperature of each mouse was monitored and maintained within 0.5°C.

Statistics

Data were analyzed using an analysis of variance (ANOVA) in all cases.

Results

20 Behavioral testing

Clinically, vincristine causes a mixed sensory-motor neuropathy, with distal motor weakness as the most prominent early sign. We therefore made use of a simple behavioral test to ascertain the motor strength of the animals in each group. The data from the incline test are summarized in Table 1 and Fig. 1. The animals treated with vincristine alone were able to maintain their grip for only about half the maximal time. The other groups tested were all able to maintain their grips for approximately the full 30 seconds allowed. The vincristine alone treated group differed from the other groups with a $p < 0.0001$ by ANOVA.

- 12 -

E1 ctr physi logical results

Motor conduction was measured from the tibial nerve, and the results are summarized in Table 2 and Fig.

2. The group treated with vincristine alone had a
5 prolonged latency and a significantly reduced action potential amplitude as compared to the control group ($p < 0.02$ by ANOVA). The groups co-treated with IGF-I did not differ significantly from the control group.

Compound recordings were conducted from the caudal
10 nerve in the tail and the results are summarized in Table 3 and Fig. 3. Here too, the vincristine alone treated group had significantly prolonged latencies and reduced amplitudes ($p < 0.001$ and $p < 0.05$ respectively). In each case IGF-I administration partially though not completely
15 improved upon these values.

Sensory recordings were conducted from the sural nerve and the values summarized in Table 4. There were no statistically significant differences between any of the groups as determined by this measurement of purely
20 sensory function.

The data presented indicate that co-administration of IGF-I with vincristine can prevent the manifestations of vincristine neuropathy seen in this animal model. Applicants have demonstrated the presence of neuropathy
25 using both behavioral and electrophysiological measurements. This animal model of vincristine neuropathy appears to correlate well with the human clinical condition in that motor dysfunction is the most prominent manifestation. Wherever vincristine
30 administration impaired the function of the peripheral nerve, IGF-I administration resulted in a significant improvement.

- 13 -

Experimental Example: Taxol

To assess whether rhIGF-I could prevent development of a sensory neuropathy caused by taxol administration, male CD-1 mice were dosed daily with taxol (21.6 mg/kg) administered intraperitoneally for 6 days in taxol-vehicle (12% chromophore EL (Sigma, St. Louis MO), 76% phosphate-buffered saline, 12% ethanol). rhIGF-I vehicle (100 mM acetic acid, 50 mM NaCl, 1% human serum albumin) or rhIGF-I (1 mg/kg) was administered subcutaneously for 10 days beginning one day prior to the start of the taxol injections. On the last day of rhIGF-I vehicle or rhIGF-I administration, the ability of mice to sense and respond to a noxious stimulus was assessed by determining hot-plate (55°C) and tail-flick latencies (D'Amour et al. *J. Pharmacol. Exp. Ther.* 72:74-79, 1941; Eddy et al. *J. Pharmacol. Exp. Ther.* 107:385-393, 1953; Vaught et al. *Life Sci.* 48:2233-2241, 1991). Hot-plate and tail-flick latencies were determined twice for each mouse. The cutoff time to lick one hindpaw or shake a hindpaw three times in the hot-plate assay was 20 sec and to move its tail from a heated coil in the tail-flick assay was 10 sec. Significant differences between vehicle and taxol-treatment groups were determined by Dunnett's t-test (Tallarida et al. Manual of Pharmacologic Calculation with Computer Programs, 2nd ed. Springer-Verlag, NY, pp. 145-148, 1987) and differences between all groups by a Newman-Keul's test (Tallarida et al. *supra*, pp. 121-125).

Only the mice treated with taxol/rhIGF-I vehicle had tail-flick and hot plate latencies that were significantly greater than that of vehicle-treated mice. Taxol significantly increased tail-flick and hot-plate latencies 43% and 37%, respectively. In addition, the tail-flick and hot-plate latencies for the taxol-treated mice were also significantly greater than that of mice

- 14 -

treated with rhIGF-I or taxol/rhIGF-I. Thus, rhIGF-I prevented the development of a sensory neuropathy as measured by changes in tail-flick and hot-plate latencies.

5 The effect of rhIGF-1 administration on preventing taxol-induced neuropathy is shown in Table 6, in Fig. 4 (tail-flick latencies) and in Fig. 5 (hot plate latencies). Results are presented as mean + S.E.M. The symbol * denotes that the value is significantly
10 different from both vehicles rhIGF-I alone, and taxol/rhIGF-I-treated groups $p < 0.05$.

Therapy

Any of the IGF-I neuropathy-reducing agents described herein can be administered to a patient in a
15 pharmaceutically-acceptable buffer (e.g., physiological saline or acetic acid buffer). Although it may be convenient to administer IGF-I or IGF-III subcutaneously, orally, nasally, or topically, e.g., as a liquid or spray, the therapeutic preparation is administered in
20 accordance with the condition to be treated. For example, it may be necessary to administer IGF-I intravenously, or surgically to the appropriate tissue, or via a catheter.

An appropriate dosage is an amount of an insulin-like growth factor-I, fragment or analog which effects a
25 reduction in the extent of neuropathy. IGF-I, for example, can be administered at dosages of .03-10 mg/kg/unit dose, as a bolus or by infusion, administered either daily, intermittently, or according to need. This
30 dosage corresponds approximately to the weight to weight ratio of IGF-I to vincristine of between 1:400 and 75:1, preferably 1:40 to 8:1. Dosages of other insulin-like growth factor-I's, fragments or analogs, or their weight to weight ratios relative to the toxic agent of instance,

- 15 -

can be determined by one skilled in the art, according to the methods described herein.

The effectiveness of treating neuropathies with IGF-I can be evaluated by the following signs of recovery: 1) Recovery of normal sensory function, which can be assessed by thermal sensitivity of the extremities; 2) Recovery of normal motor function, which can be assessed by measures of muscle weakness, fine motor control, and deep tendon reflexes; and 3) Normalization of nerve conduction velocity, which is assessed electrophysiologically. Methods for assessing peripheral neuropathy are described by Asbury et al. (Asbury et al., 1992, in Diseases of the Nervous System, Clinical Neurobiology, eds. Asbury et al. W.B. Saunders Inc. Philadelphia, PA. 1:252-269) and can be employed by those skilled in the art to determine the effectiveness of an insulin-like growth factor-I in alleviating neuropathy.

Other Embodiments

Other embodiments are within the following claims. For example, agents useful in reducing toxic neuropathy can include any of the family of insulin-like growth factor-I's and related neurotrophins, nerve growth factor-enhancing molecules, ciliary neurotrophic factor, IGF-I derived peptide fragments, analogs of an insulin-like growth factor-I, or combinations of these agents.

While vincristine neurotoxicity most typically is manifested as a peripheral neuropathy, the method of the invention can also be used to reduce other toxic neuropathies, e.g., neuropathies of the autonomic or cranial nervous systems, and can be used to mitigate the effects of other toxic agents.

The invention further includes neuropathies associated with systemic diseases: uremia, childhood cholestatic liver disease, chronic respiratory

- 16 -

insufficiency, alcoholic polyneuropathy, multiple organ failure, sepsis, hypoalbuminemia, eosinophilia-myalgia syndrome, hepatitis, porphyria, hypoglycemia, vitamin deficiency, chronic liver disease, primary biliary

5 cirrhosis, hyperlipidemia, leprosy, Lyme disease, herpes zoster, Guillain-Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, sensory perineuritis, acquired immunodeficiency syndrome (AIDS)-associated neuropathy, Sjogren's syndrome, primary

10 vasculitis (such as polyarteritis nodosa), allergic granulomatous angiitis (Churg-Strauss), hypersensitivity angiitis, Wegener's granulomatosis, rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, scleroderma, sarcoidosis, vasculitis, systemic

15 vasculitides, acute inflammatory demyelinating polyneuropathy, post-polio syndrome, carpal tunnel syndrome, pandysautonomia, primary systemic amyloidosis, hypothyroidism, chronic obstructive pulmonary disease, acromegaly, malabsorption (sprue, celiac disease),

20 carcinomas (sensory, sensorimotor, late and demyelinating), lymphoma (including Hodgkin's), polycythemia vera, multiple myeloma (lytic type, osteosclerotic, or solitary plasmacytoma), benign monoclonal gammopathy, macroglobulinemia, and

25 cryoglobulinemia, as described by Asbury et al. *supra*, herein incorporated by reference.

The invention also includes genetically acquired neuropathies: peroneal muscular atrophy (Charcot-Marie-Tooth Disease, types I, II, and X), hereditary amyloid

30 neuropathies, hereditary sensory neuropathy (type I and type II), porphyric neuropathy, hereditary liability to pressure palsy, Fabry's disease, adrenomyeloneuropathy, Riley-Day syndrome, Dejerine-Sottas neuropathy (hereditary motor-sensory neuropathy-III), Refsum's

35 disease, ataxia-telangiectasia, hereditary tyrosinemia,

- 17 -

anaphalipoproteinemia, abetalipoproteinemia, giant axonal neuropathy, metachromatic leukodystrophy, globoid cell leukodystrophy, and Friedrich's ataxia (Asbury et al. *supra*). Also included in the invention are

5 mononeuropathy multiplex, plexopathy, and pure motor neuropathy, as described by Asbury et al. *supra*.

- 18 -

TABLE 1

GROUP	INCLINE TEST (sec)	
	MEANS	S.E.M.
CONTROL	27.6	2.4
VIN ALONE	15.4*	6.5
VIN + IGF LOW	30	0
VIN + IGF HIGH	27.7	2.3
IGF LOW	30	0
IGF HIGH	27	3

Data from the incline test. Values represent the time the animals could remain suspended from a verticle incline, with a maximum set at 30 seconds.

* Means this value differed from the other groups with a $p < 0.0001$

- 19 -

TABLE 2

GROUP	TIBIAL - MOTOR NERVE			
	LATENCY (msec)		AMPLITUDE (mV)	
	MEAN	S.E.M.	MEAN	S.E.M.
CONTROL	1.21	0.03	22.98	1.06
VIN ALONE	1.35	0.05	13.94*	2.11
VIN + IGF LOW	1.38	0.05	17.12	1.53
VIN + IGF HIGH	1.43	0.08	18.48	1.89
IGF LOW	1.21	0.02	19.8	1.81
IGF HIGH	1.23	0.03	20.76	1.47

Electrophysiological measurements from the tibial nerve.

* Signifies that this group differed from the control with a
 $p < 0.02$.

- 20 -

TABLE 3

GROUP	CAUDAL - COMPOUND NERVE			
	LATENCY (msec)		AMPLITUDE (mV)	
	MEAN	S.E.M.	MEAN	S.E.M.
CONTROL	1.39	0.03	57.32	3.47
VIN ALONE	1.74**	0.09	30.66*	8.56
VIN + IGF LOW	1.55*	0.03	37.01*	2.59
VIN + IGF HIGH	1.58*	0.03	36.05*	1.65
IGF LOW	1.46	0.03	55.93	5.68
IGF HIGH	1.45	0.03	51.96	4.25

Electrophysiological measurements from the caudal nerve.

* Signifies that these values differed from the control with a $p < 0.05$.

** Signifies that this value differed from the control with a $p < 0.001$.

- 21 -

TABLE 4

GROUP	SURAL - SENSORY NERVE			
	LATENCY (msec)		AMPLITUDE (mV)	
	MEAN	S.E.M.	MEAN	S.E.M.
CONTROL	0.54	0.01	35.29	3.55
VIN ALONE	0.62	0.04	55.66	7.46
VIN + IGF LOW	0.61	0.02	44.49	7.09
VIN + IGF HIGH	0.57	0.03	37.27	5.4
IGF LOW	0.55	0.02	30.52	3.34
IGF HIGH	0.5	0.02	43.06	7.73

Electrophysiological measurements from the sural nerve. There were no statistically significant differences among groups.

- 22 -

TABLE 5

AGENTS THAT CAUSE PERIPHERAL NEUROPATHY

AGENT	ACTIVITY
acetazolamide	diuretic
acrylamide	flocculent, grouting agent
adriamycin	antineoplastic
alcohol (ethanol)	solvent, recreational drug
almitrine	respiratory stimulant
amiodarone	antiarrhythmic
amphotericin	antimicrobial
arsenic	herbicide, insecticide
aurothioglucose	antirheumatic
barbiturates	anticonvulsant, sedative
buckthorn	toxic berry
carbamates	insecticide
carbon disulfide (CS ₂)	industrial
chloramphenicol	antibacterial
chloroquine	antimalarial
cholestyramine	antihyperlipoproteinemic
cisplatin	antineoplastic
clioquinol	amebicide, antibacterial
colestipol	antihyperlipoproteinemic
colchicine	gout suppressant
colistin	antimicrobial
cycloserine	antibacterial
cytarabine	antineoplastic
dapsone	dermatologic including leprosy
dideoxycytidine	antineoplastic
dideoxyinosine	antineoplastic
dideoxythymidine	antiviral
disulfiram	antialcohol
doxorubicin	antineoplastic
ethambutol	antibacterial
ethionamide	antibacterial
glutethimide	sedative, hypnotic
gold	antirheumatic
hexacarbons	solvents
hormonal contraceptives	
hexamethylmelamine	fireproofing, creaseproofing
hydralazine	antihypertensive
hydroxychloroquine	antirheumatic

- 23 -

TABLE 5 CONT.

AGENT	ACTIVITY
imipramine	antidepressant
indomethacin	anti-inflammatory
inorganic lead	toxic metal in paint, etc.
isoniazid	antituberculous
lithium	antidepressant
methylmercury	industrial waste
metformin	antidiabetic
methylhydrazine	synthetic intermediate
metronidazole	antiprotozoal
misonidazole	radiosensitizer
nitrofurantoin	urinary antiseptic
nitrogen mustard	antineoplastic, nerve gas
nitrous oxide	anesthetic
organophosphates	insecticides
ospolot	anticonvulsant
penicillin	antibacterial
perhexiline	antiarrhythmic
perhexiline maleate	antiarrhythmic
phenytoin	anticonvulsant
platinum	drug component
primidone	anticonvulsant
procarbazine	antineoplastic
pyridoxine	vitamin B6
sodium cyanate	anti-sickling
streptomycin	antimicrobial
sulphonamides	antimicrobial
suramin	antineoplastic
tamoxifen	antineoplastic
taxol	antineoplastic
thalidomide	antileprous
thallium	rat poison
triamterene	diuretic
trimethyltin	toxic metal
L-tryptophan	health food additive
vincristine	antineoplastic
vinblastine	antineoplastic
vindesine	antineoplastic
vitamin A	mega doses
vitamin D	mega doses

- 24 -

TABLE 6

EFFECT OF TAXOL AND rhIGF-I ON TAIL-FLICK
AND HOT-PLATE LATENCIES

Treatment ^{a,b}	Tail-Flick Latency (sec)	Hot-Plate Latency (sec)
rhIGF-I Vehicle	3.49 ± 0.15	8.72 ± 0.40
Taxol Vehicle	3.70 ± 0.30	7.34 ± 0.44
rhIGF-I (1mg/kg)	3.43 ± 0.14	8.10 ± 0.39
Taxol/rhIGF-I Vehicle	4.99 ± 0.15*	11.96 ± 0.54*
Taxol/rhIGF-I	3.70 ± 0.19	7.74 ± 0.61

* Significantly different from vehicle, rhIGF-I or Taxol/rhIGF-I treated groups p<0.05.

^a rhIGF-I Vehicle: The vehicle used for rhIGF-I was administered to one group of animals to serve as a control group, without rhIGF-I itself.

Taxol Vehicle: The vehicle used for Taxol was administered to one group of animals to serve as a control group, without Taxol itself.

rhIGF-I (1mg/kg): rhIGF-I in its vehicle was administered as described.

Taxol/rhIGF-I Vehicle: Taxol in its vehicle was administered to one group of animals concurrently with the vehicle for rhIGF-I, but without rhIGF-I itself.

Taxol/rhIGF-I: Both taxol in its vehicle and rhIGF-I in its vehicle were administered as described.

^b Vehicle control groups are routinely performed to ensure that the vehicle carrying the agent to be tested has no effects on its own.

- 25 -

SEQUENCE LISTING**(1) GENERAL INFORMATION:**

- (i) **APPLICANT:** Cephalon, Inc.
Albert Einstein College of
Medicine of Yeshiva
University
- (ii) **TITLE OF INVENTION:** PREVENTION AND TREATMENT OF
PERIPHERAL NEUROPATHY
- (iii) **NUMBER OF SEQUENCES:** 1
- (iv) **CORRESPONDENCE ADDRESS:**
- (A) **ADDRESSEE:** Fish & Richardson
(B) **STREET:** 225 Franklin Street
(C) **CITY:** Boston
(D) **STATE:** Massachusetts
(E) **COUNTRY:** U.S.A.
(F) **ZIP:** 02110-2804
- (v) **COMPUTER READABLE FORM:**
- (A) **MEDIUM TYPE:** 3.5" Diskette, 1.44 Mb
(B) **COMPUTER:** IBM PS/2 Model 50Z or 55SX
(C) **OPERATING SYSTEM:** IBM P.C. DOS (Version 3.30)
(D) **SOFTWARE:** WordPerfect (Version 5.0)
- (vi) **CURRENT APPLICATION DATA:**
- (A) **APPLICATION NUMBER:**
(B) **FILING DATE:**
(C) **CLASSIFICATION:**
- (vii) **PRIOR APPLICATION DATA:**
- (A) **APPLICATION NUMBER:** 07/899,070
(B) **FILING DATE:** June 12, 1992
- (viii) **ATTORNEY/AGENT INFORMATION:**
- (A) **NAME:** Paul T. Clark
(B) **REGISTRATION NUMBER:** 30,162
(C) **REFERENCE/DOCKET NUMBER:** 02655/026001

- 26 -

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 542-5070
(B) TELEFAX: (617) 542-8906
(C) TELEX: 200154

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1:**(i) SEQUENCE CHARACTERISTICS:**

(A) LENGTH: 16
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Arg Arg Leu Glu Met Tyr Cys Ala Pro Leu Lys Pro Ala Lys
Ser
Ala

What is claimed is:

- 27 -

Claims

1. A method of reducing a peripheral neuropathy that is not caused by an abnormal insulin level in a mammal, said method comprising
5 administering a neuropathy-reducing amount of insulin-like growth factor-I (IGF-I) or insulin-like growth factor-III (IGF-III) to said mammal.
2. The method of claim 1, wherein said mammal is a human.
- 10 3. The method of claim 1, wherein said insulin-like growth factor-I is administered intravenously or subcutaneously.
4. The method of claim 1, wherein there is administered IGF-III.
- 15 5. The method of claim 1, wherein said neuropathy is associated with a systemic disease.
6. The method of claim 1, wherein said neuropathy is post-polio syndrome.
7. The method of claim 1, wherein said neuropathy
20 is hereditary neuropathy.
8. The method of claim 7, wherein said neuropathy is Charcot-Marie-Tooth Disease.
9. The method of claim 1, wherein said neuropathy is caused by a toxic agent.

- 28 -

10. The method of claim 9, wherein said toxic agent is a chemotherapeutic agent.

11. The method of claim 10, wherein said insulin-like growth factor-I is administered simultaneously with
5 said chemotherapeutic agent.

12. The method of claim 10, wherein said chemotherapeutic agent is vincristine.

13. The method of claim 10, wherein said chemotherapeutic agent is taxol.

10 14. The method of claim 10, wherein said chemotherapeutic agent is cisplatin.

15. The method of claim 10, wherein said chemotherapeutic agent is dideoxyinosine.

16. The method of claim 12, wherein the weight to
15 weight ratio of said insulin-like growth factor-I to said vincristine is between 1:400 and 75:1.

17. The method of claim 16, wherein said ratio is between 1:40 and 8:1.

18. The method of claim 10, wherein said insulin-
20 like growth factor-I is administered to said mammal following chemotherapy to restore at least a portion of the neurofunction destroyed by said chemotherapy.

19. The method of claim 9, wherein said toxic agent comprises alcohol, a metal, an industrial toxin, a
25 drug, a vitamin, a contaminant of a food, or a contaminant of a medicinal.


- 29 -

20. A composition comprising a substantially pure insulin-like growth factor-I and a chemotherapeutic agent, in a weight to weight ratio of between 1:400 and 75:1.

5 21. The composition of claim 20, wherein said insulin-like growth factor-I is IGF-III.

22. The composition of claim 20, wherein said chemotherapeutic agent is vincristine, cisplatin, taxol, or dideoxyinosine.²

1/5

EFFECT OF rhIGF-I ON MOTOR FUNCTION
AFTER VINCRISTINE TREATMENT

2/5


EFFECT OF rhIGF-I ON TIBIAL NERVE FUNCTION
AFTER VINCRISTINE TREATMENT

FIG. 2

3/5


EFFECT OF rhIGF-I ON CAUDAL NERVE FUNCTION
AFTER VINCRISTINE TREATMENT

FIG. 3




FIG. 4




FIG. 5

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61K 37/02, 37/24, 37/36

US CL :514/4, 12, 21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/4, 12, 21

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS: IGF, neuropathy, Chemo

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	US, A, 4,863,902 (Amagase et al) 05 September 1989, see the entire patent particularly the abstract, column 10, lines 55-68 and column 11, lines 1-14 and 36-56.	1-3,5-15, <u>18, 19</u> 16,17,20-22
Y	US, A, 5,068,224 (Fryklund et al) 26 November 1991, see the Invention, column 6 and abstract.	1-3,5-8
Y	WO, A, 89/05822 (Ballard et al) 29 June 1989, see page 4 first paragraph.	4

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be part of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 NOVEMBER 1993

Date of mailing of the international search report

21 SEP 1993

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

FATEMEH T. MOEZIE

Telephone No. (703) 308-0196